Athenex Inc logo

ATNX - Athenex Inc Share Price

$15.27 -0.2  -1.1%

Last Trade - 17/01/20

Sector
Healthcare
Size
Mid Cap
Market Cap £909.4m
Enterprise Value £861.9m
Revenue £67.8m
Position in Universe 2320th / 6415
Bullish
Bearish
Unlock ATNX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ATNX Revenue Unlock ATNX Revenue

Net Income

ATNX Net Income Unlock ATNX Revenue

Normalised EPS

ATNX Normalised EPS Unlock ATNX Revenue

PE Ratio Range

ATNX PE Ratio Range Unlock ATNX Revenue

Dividend Yield Range

ATNX Dividend Yield Range Unlock ATNX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ATNX EPS Forecasts Unlock ATNX Revenue
Profile Summary

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated November 4, 2003
Public Since June 14, 2017
No. of Shareholders: 133
No. of Employees: 575
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 77,469,385
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ATNX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ATNX
Upcoming Events for ATNX
Similar to ATNX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.